Protocol Ledger

NCT07407465 · Phase II · RECRUITING

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Interventional Phase II clinical trial protocol NCT07407465 sponsored by Gruppo Oncologico del Nord-Ovest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-20 Enrollment: 42 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07407465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07407465
Protocol FieldVerified Registry Value
NCT IdentifierNCT07407465
Consolidated Lead SponsorGruppo Oncologico del Nord-Ovest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment42 participants (ESTIMATED)
Registered Start Date2025-10-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07407465
Hospital Research SiteLocationSite Profile
Hopital Saint-LouisParis, FranceOpen Hospital Dossier ->
Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI